Where are the new drugs? pg. 6
The federal efforts have their share of skeptics, including Steven Paul, M.D., president of Lilly Research Laboratories. “I am worried that obtaining the kind of molecular probes required for even in vivo testing may prove to be too time-consuming and expensive,” Paul says, “and may divert precious NIH funds away from basic or clinical biomedical research.”
The federal initiatives in no way are meant to diminish government’s role in supporting fundamental discovery, Austin responds. Tools developed by the public sector, however, can help establish the therapeutic potential of new compounds, and encourage industry to push them through the pipeline.
“As long as… we’re all aware of what we can do and can’t do, I think we’ll be fine,” he says.